| Literature DB >> 35706375 |
Jing Zhou1, Dayang Chai1, Yuxiang Dai2, Aichao Wang1, Ting Yan3, Shu Lu1.
Abstract
We aimed to investigate prognostic factors of in-stent restenosis (ISR) within 3 years in older acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation and establish a clinical model for predicting ISR. We retrospectively collected 215 older ACS patients who followed coronary angiography (CAG) after DES implantation, divided into ISR group and non in-stent restenosis (non-ISR) group according to the results of reviewed CAG. Logistic regression analysis was performed to screen independent predictors related to ISR and build the clinical predictive model, which clinical application was assessed by decision curve analysis (DCA) and clinical impact curve (CIC). Kaplan-Meier survival curves for ISR by independent predictors. In multivariate logistic regression analysis showed that the red cell distribution width (RDW) was higher in ISR group compared with non-ISR (odds ratio (OR) = 1.54, 95% confidence interval (CI): 1.14-2.08, p < 0.01). Instead, a negative correlation was observed between minimum stent diameter and ISR (OR = 0.28, 95%CI:0.09-0.86, p = 0.03). A novel nomogram composed of these significant features presented a concordance index (C-index) of 0.710, DCA and CIC suggested that the predictive nomogram had clinical utility. Schoenfeld residuals showed the model RDW ≥ 12.6% with minimum stent diameter <3 mm was consistent with the proportional risk assumption. The Kaplan-Meier estimate for ISR showed statistical significance. Higher levels of RDW and lower minimum stent diameter were associated with incidence of ISR within 3 years in older ACS patients after DES implantation.Entities:
Keywords: drug-eluting stent; in-stent restenosis; kaplan-meier curve; nomogram; older patients
Mesh:
Year: 2022 PMID: 35706375 PMCID: PMC9208031 DOI: 10.1177/10760296221107888
Source DB: PubMed Journal: Clin Appl Thromb Hemost ISSN: 1076-0296 Impact factor: 3.512
Figure 1.Study Flowchart
Baseline Characteristics
| ISR (n = 30) | non-ISR (n = 185) |
| |
|---|---|---|---|
| Age, yrs | 71.1 ± 5.6 | 71.9 ± 5.7 | 0.48 |
| Male | 12 (40.0) | 49 (26.5) | 0.13 |
| Current smoker | 11 (36.7) | 74 (40.0) | 0.73 |
| Hypertension | 23 (76.7) | 139 (75.1) | 0.86 |
| Diabetes mellitus | 9 (30.0) | 52 (28.1) | 0.83 |
|
| |||
| HbA1c, % | 6.15 ± 0.86 | 6.30 ± 1.06 | 0.45 |
| TC, mmol/L | 3.45 ± 0.79 | 3.48 ± 0.89 | 0.86 |
| TG, mmol/L | 1.57 ± 0.85 | 1.55 ± 0.96 | 0.92 |
| LDL-C, mmol/L | 1.63 ± 0.65 | 1.68 ± 0.81 | 0.76 |
| HDL-C, mmol/L | 1.13 ± 0.23 | 1.13 ± 0.29 | 0.97 |
| NHDL-C, mg/dl | 2.31 ± 0.82 | 2.33 ± 0.86 | 0.92 |
| apoA1, g/L | 1.35 ± 0.24 | 1.33 ± 0.21 | 0.68 |
| apoB, g/L | 0.67 ± 0.20 | 0.71 ± 0.25 | 0.43 |
| LPa, mg/dl | 177.5 (99.5, 391.5) | 142.0 (70.0, 394.0) | 0.51 |
| HDL-C apoA1 ratio | 0.84 ± 0.14 | 0.85 ± 0.17 | 0.87 |
| NHDL-C apoB ratio | 1.33 ± 0.23 | 1.29 ± 0.22 | 0.34 |
| ApoB apoA1 ratio | 0.51 ± 0.16 | 0.54 ± 0.21 | 0.36 |
| TG HDL-C ratio | 1.52 ± 1.10 | 1.52 ± 1.18 | 0.99 |
| WBC, 10^9/L | 6.16 ± 1.23 | 6.35 ± 1.89 | 0.60 |
| Hemoglobin, g/L | 129.7 ± 16.4 | 132.9 ± 14.1 | 0.27 |
| Platelet, 10^9/L | 199.9 ± 54.9 | 192.1 ± 53.3 | 0.46 |
| Neutrophil, 10^9/L | 3.71 ± 0.93 | 3.85 ± 1.56 | 0.64 |
| Lymphocyte, 10^9/L | 1.73 ± 0.41 | 1.69 ± 0.63 | 0.74 |
| Monocyte, 10^9/L | 0.52 ± 0.14 | 0.54 ± 0.19 | 0.51 |
| RDW, % | 12.8 (12.4, 14.0) | 12.5 (12.1, 13.1) | 0.02 |
| PDW, % | 12.77 ± 1.72 | 13.15 ± 2.77 | 0.48 |
| fibrinogen, mg/dl | 264.6 ± 56.0 | 271.4 ± 62.7 | 0.58 |
| Platelet lymphocyte ratio | 121.8 ± 42.1 | 126.3 ± 52.0 | 0.66 |
| Neutrophil lymphocyte ratio | 2.24 ± 0.71 | 2.60 ± 1.83 | 0.30 |
|
| |||
| DAPT* | 27 (90.0) | 180 (97.3) | 0.09 |
| Statin | 18 (60.0) | 103 (55.7) | 0.66 |
| ACEI/ARB | 9 (30.0) | 62 (33.5) | 0.70 |
| β-blockers | 16 (53.3) | 85 (45.9) | 0.45 |
|
| |||
| Number of stents per target lesion | 1.53 ± 0.57 | 1.39 ± 0.62 | 0.25 |
| Length of stents per target lesion, mm | 43.1 ± 18.7 | 38.2 ± 20.8 | 0.22 |
| Overlapped of stents | 15 (50.0) | 58 (31.4) | 0.04 |
| Diameter of minimum stent, mm | 2.73 ± 0.34 | 2.99 ± 0.46 | 0.004 |
| Proximal optimization technique (POT) | 25 (83.3) | 169 (91.4) | 0.19 |
|
| |||
| Chronic total occulusion | 5 (16.7) | 37 (20.0) | 0.67 |
| Complex bifurcation lesions | 4 (13.3) | 22 (11.9) | 0.77 |
| Ostial lesions | 6 (10.0) | 25 (13.5) | 0.40 |
|
| |||
| Left main trunk | 0 (0) | 13 (7.0) | 0.22 |
| Left anterior descending artery | 15 (50.0) | 84 (45.4) | 0.64 |
| Left circumflex artery | 4 (13.3) | 30 (16.2) | 0.90 |
| Right coronary artery | 14 (46.7) | 68 (36.8) | 0.30 |
Data are presented as N (%), mean ± (SD) and median interquartile range in parentheses.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; apoA1, ApolipoproteinA1; apoB, ApolipoproteinB; ARB, angiotensin receptor blocker; HbA1c, Hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; ISR, in-stent restenosis; LDL-C, low-density lipoprotein cholesterol; NHDL-C, non-high-density lipoprotein cholesterol; non-ISR, non in-stent restenosis; PDW, platelet distribution width; RDW, red cell distribution width; TC, total cholesterol; TG, triglyceride; WBC, white blood cell
DAPT*: Dual Anti-Platelet Therapy in the first year after PCI
Univariate and Multivariate logistic regression analysis for predictors of ISR for older patients in pre-PCI
| variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI |
| OR | 95%CI |
| |
| RDW (%) | 1.60 | 1.20-2.13 | <0.01 | 1.54 | 1.14-2.08 | <0.01 |
| DAPT* | 0.25 | 0.06-1.11 | 0.07 | - | - | - |
| Overlapped of stents | 2.19 | 1.04-4.78 | 0.04 | 1.56 | 0.67-3.61 | 0.30 |
| Minimum stent diameter (mm) | 0.21 | 0.07-0.65 | <0.01 | 0.28 | 0.09-0.86 | 0.03 |
Abbreviations: CI, confidence interval; OR, odds ratio; RDW, red cell distribution width;
DAPT*: Dual Anti-Platelet Therapy in the first year after PCI
Figure 3.A: ROC curves; B: Decision curve analysis; C: Clinical impact curves
Figure 2.Nomogram to pridict ISR in older ACS patients after DES implantation and calibration curve
Figure 4.Schoenfeld Residuals Test
Figure 5.Kaplan-Meier curves for survival probability